Brainsway Ltd (BWAY)
NASDAQ:BWAY
BWAY Stock Chart & Stats
$13.86
-$0.11(-1.13%)
At close: 4:00 PM EST
$13.86
-$0.11(-1.13%)
Day’s Range― - ―
52-Week Range$3.92 - $14.65
Previous CloseN/A
Volume9.67K
Average Volume (3M)186.00K
Market Cap
$561.47M
Enterprise Value$483.56M
Total Cash (Recent Filing)$67.95M
Total Debt (Recent Filing)$6.82M
Price to Earnings (P/E)23.6
Beta1.41
Next Earnings
May 13, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding40,033,028
10 Day Avg. Volume238,731
30 Day Avg. Volume185,995
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.48
Price to Sales (P/S)3.45
P/FCF Ratio11.06
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue9.24
Enterprise Value/Gross Profit12.26
Enterprise Value/Ebitda48.32
Forecast
1Y Price Target
$15.00Price Target Upside8.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.18
Revenue Forecast (FY)$64.81M
Bulls Say, Bears Say
Bulls Say
Profitability & Cash GenerationBrainsWay's shift to sustained profitability with high gross margins and positive free cash flow improves financial resilience. Durable cash generation supports reinvestment, lease financing and minority investments, reducing reliance on external funding and enabling strategic growth over the next several years.
Growing Installed Base & Recurring RevenueA larger installed base and a shift toward multiyear leases create recurring, visible revenue and higher customer retention. Lease-driven engagements raise utilization and aftermarket service opportunity, bolstering predictable cash flows and supporting scaling of consumables and service margins over time.
Regulatory & Reimbursement MomentumLabel expansions and insurer policy changes materially broaden addressable markets and reduce access friction. Durable regulatory clearances plus evolving payer coverage lower adoption barriers, accelerating clinic uptake and utilization, and enhancing long-term revenue prospects for both adolescent and accelerated-treatment cohorts.
Bears Say
Cash Flow & Margin VolatilityDespite recent cash-flow improvement, BrainsWay's history of volatile free cash flow and sensitivity to working-capital and investment timing creates execution risk. Such swings can constrain reinvestment, make planning for lease financing and inventory trickier, and magnify stress if growth slows.
Rising Operating ExpensesHigher S&M and R&D spending to drive adoption and clinical programs can pressure margins if utilization or reimbursement lags. The recent dip in adjusted EBITDA margins highlights risk that elevated reinvestment could outpace revenue growth, making profitability sensitive to execution over the medium term.
Emerging Competitive/Channel RiskAt-home neuromodulation approvals enable alternative treatment channels that could shift care away from clinic-based Deep TMS. Even as BrainsWay has an investment link to Neurolief, broader at-home adoption and different reimbursement dynamics pose a structural competitive risk to clinic system placements and long-term consumable/service revenues.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $3.92 and its highest was $14.65 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $561.47M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is May 13, 2026 which is in 47 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Mar 11, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.039.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Undervalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.03.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,033,028 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.07 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 8.34%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (8.23% Upside)
$15.00 (8.23% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 254.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 23.6%
Last 30 Days ▲ 23.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
186.65%
12-Months-Change
Fundamentals
Return on Equity
12.01%
Trailing 12-Months
Asset Growth
19.72%
Trailing 12-Months
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Company Deck
BWAY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
BrainsWay's Q3 2025 earnings call indicated strong growth and positive developments, including record revenue, increased system shipments, and successful strategic investments. Despite increased operating expenses and a delay in FDA clearance for Neurolief, the company's performance and raised guidance reflect a generally optimistic outlook.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$15.00
▲(8.23% Upside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
―
Insiders
0.46% Mutual Funds
11.63% Other Institutional Investors
87.30% Public Companies and
Individual Investors